Jubilant HollisterStier (JHS), a U.S.-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, has appointed Chris Preti as President. He brings more than 25 years of pharmaceutical industry experience in R&D, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President. 
 
As previously announced in May 2022, Jubilant HollisterStier’s expansion plan is investing approximately $285 million to double its capacity for fill and finish of sterile injectables at its Spokane, WA facility. The investment is part of the company’s cooperative agreement providing $149.6 million from the U.S. Government to expand its critical vaccine manufacturing capacity in the U.S.


 
Chris Preti said, “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide. As a leading contract manufacturer of injectable pharmaceutical products and sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, we are acutely aware of the supply chain issues that continue to challenge manufacturers. With this expansion, we are well-positioned to address the contract manufacturing needs of major producers throughout North America. My decades in the Pharma industry taught me the critical role of manufacturing in achieving commercial success, and I am delighted to be heading up an industry leader committed to providing the highest quality comprehensive services in partnership with our customers.”